$12.08
+0.17 (+1.43%)
Open$11.90
Previous Close$11.91
Day High$12.17
Day Low$11.63
52W High$12.48
52W Low$1.13
Volume—
Avg Volume1.23M
Market Cap568.92M
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+116.1% upside
Current
$12.08
$12.08
Target
$26.11
$26.11
$17.52
$26.11 avg
$31.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 93.03M | 87.17M | 93.25M |
| Net Income | -25,402,018 | -21,372,578 | -19,024,947 |
| Profit Margin | -27.3% | -24.5% | -20.4% |
| EBITDA | -33,224,495 | -30,585,289 | -30,503,356 |
| Free Cash Flow | -14,578,727 | -14,999,377 | -17,296,703 |
| Rev Growth | -8.3% | +13.0% | +19.4% |
| Debt/Equity | 0.78 | 0.63 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |